Malignant cardiac tumors present a major therapeutic challenge. Results with primary resection and adjuvant chemotherapy are poor at best, with survival rare beyond 1 year. Complete resection with ...
Working in close partnership with patients, scientists at the Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute, and Count Me In have identified new causes of a rare cancer of blood ...
An Angiosarcoma patient facing a grave prognosis found a lifeline in a repurposed PD-1 inhibitor, a treatment hidden in the medical literature for three years. Every Cure and its partners are building ...
Prospective Randomized Study Comparing Docetaxel, Estramustine, and Prednisone With Docetaxel and Prednisone in Metastatic Hormone-Refractory Prostate Cancer Thirty patients were entered onto the ...
Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute's (NCI) Division of Cancer Diagnosis and Treatment (DCTD), part of the National ...
Cases coded as “angiosarcoma” were retrieved from the Oral and Maxillofacial Pathology Registry of the Armed Forces Institute of Pathology. Patient folders and pathology were reviewed and recorded; ...
Angiosarcoma is a rare and aggressive disease. It is a tumor of the interior lining of the blood vessels and may occur in any part of the body. Normally, it can be found in the head and neck region, ...
Angiosarcoma is an aggressive malignancy of endothelial differentiation. Potential roles of the endothelial angiopoietin-tunica interna endothelial cell kinase (ANGPT-TIE) system in angiosarcoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback